Biden’s Move to Reclassify Marijuana: Impacts on Healthcare and Market

President Joe Biden’s recent decision to reclassify marijuana from a Schedule I to a less dangerous classification marks a significant shift in U.S. drug policy. This reclassification, long advocated by healthcare professionals and the public, is poised to unlock extensive medical research opportunities and change regulatory landscapes. The move could drastically alter how marijuana is perceived and used in medicine, with promising impacts on healthcare and market variables.